Franklin Resources’s Larimar Therapeutics LRMR Stock Holding History

Franklin Resources’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,723	Closed	-$76.3K	–	3029
2024 Q4	$76.3K	Hold	19,723	–	–	﹤0.01%	2771
2024 Q3	$143K	Buy	19,723 +3,549	+22%	+$28.5K	﹤0.01%	2705
2024 Q2	$117K	Buy	+16,174	New	+$124K	﹤0.01%	2657
2016 Q2	–	Sell	-158,309	Closed	-$12.7M	–	1527
2016 Q1	$12.7M	Sell	158,309 -6,279	-4%	-$496K	0.01%	921
2015 Q4	$12.4M	Buy	164,588 +17,729	+12%	+$2.85M	0.01%	962
2015 Q3	$56.3M	Buy	146,859 +59,885	+69%	+$27M	0.03%	522
2015 Q2	$36.1M	Buy	86,974 +21,959	+34%	+$9.19M	0.02%	723
2015 Q1	$30.9M	Buy	65,015 +3,626	+6%	+$1.72M	0.01%	768
2014 Q4	$22.7M	Sell	61,389 -2,382	-4%	-$614K	0.01%	838
2014 Q3	$15M	Buy	+63,771	New	+$14.5M	0.01%	959

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources's LRMR Position: Q1 2025 in Review

Franklin Resources sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 19,723 shares — an estimated $76.3K sold.

Franklin Resources first reported a position in LRMR in Q3 2014 and held it in 10 quarters. The position peaked at $56.3M in Q3 2015. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

Franklin Resources reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
Franklin Resources sold 19,723 Larimar Therapeutics shares in Q1 2025, an estimated $76.3K.
Franklin Resources first reported a position in Larimar Therapeutics in Q3 2014 and held it in 10 quarters.
Franklin Resources's Larimar Therapeutics position peaked at $56.3M in Q3 2015.
103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on Franklin Resources's 13F filing for Q1 2025, filed 13 May 2025.